BLUEPRINT MEDICINES CORP (BPMC)
US09627Y1091 - Common Stock
Taking everything into account, BPMC scores 3 out of 10 in our fundamental rating. BPMC was compared to 588 industry peers in the Biotechnology industry. BPMC may be in some trouble as it scores bad on both profitability and health. BPMC is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
BPMC had negative earnings in the past year.
BPMC had a negative operating cash flow in the past year.
BPMC had negative earnings in 4 of the past 5 years.
In the past 5 years BPMC reported 4 times negative operating cash flow.
1.2 Ratios
BPMC has a Return On Assets of -48.32%. This is comparable to the rest of the industry: BPMC outperforms 52.05% of its industry peers.
BPMC has a Return On Equity of -388.19%. This is in the lower half of the industry: BPMC underperforms 77.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.32% | ||
| ROE | -388.19% | ||
| ROIC | N/A |
ROA(3y)-47.02%
ROA(5y)-34.38%
ROE(3y)-187.61%
ROE(5y)-123.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BPMC has a better Gross Margin (96.53%) than 97.26% of its industry peers.
BPMC's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BPMC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.14%
GM growth 5YN/A
2. Health
2.1 Basic Checks
BPMC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BPMC has more shares outstanding
BPMC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BPMC has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.05, we must say that BPMC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BPMC (-0.05) is better than 60.45% of its industry peers.
BPMC has a Debt/Equity ratio of 1.60. This is a high value indicating a heavy dependency on external financing.
BPMC's Debt to Equity ratio of 1.60 is on the low side compared to the rest of the industry. BPMC is outperformed by 81.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.6 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.05 |
ROIC/WACCN/A
WACC9.51%
2.3 Liquidity
A Current Ratio of 3.76 indicates that BPMC has no problem at all paying its short term obligations.
BPMC has a Current ratio of 3.76. This is comparable to the rest of the industry: BPMC outperforms 42.47% of its industry peers.
A Quick Ratio of 3.66 indicates that BPMC has no problem at all paying its short term obligations.
The Quick ratio of BPMC (3.66) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.76 | ||
| Quick Ratio | 3.66 |
3. Growth
3.1 Past
BPMC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.59%, which is quite good.
The Revenue has grown by 22.28% in the past year. This is a very strong growth!
The Revenue has been growing by 41.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)10.59%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q31.32%
Revenue 1Y (TTM)22.28%
Revenue growth 3Y-32.02%
Revenue growth 5Y41.16%
Revenue growth Q2Q85.46%
3.2 Future
Based on estimates for the next years, BPMC will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.20% on average per year.
BPMC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.02% yearly.
EPS Next Y32.29%
EPS Next 2Y28.88%
EPS Next 3Y27.41%
EPS Next 5Y18.2%
Revenue Next Year60.43%
Revenue Next 2Y56.04%
Revenue Next 3Y50.19%
Revenue Next 5Y33.02%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
BPMC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BPMC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BPMC's earnings are expected to grow with 27.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.88%
EPS Next 3Y27.41%
5. Dividend
5.1 Amount
BPMC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BLUEPRINT MEDICINES CORP
NASDAQ:BPMC (4/25/2024, 7:00:01 PM)
After market: 90.73 0 (0%)90.73
-1.53 (-1.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.56B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.32% | ||
| ROE | -388.19% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.53% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.6 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.76 | ||
| Quick Ratio | 3.66 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)10.59%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y32.29%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.28%
Revenue growth 3Y-32.02%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y